Rezultati pretrage

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone od Ugo De Giorgi, Paola Caroli, Salvatore Luca Burgio, Cecilia Menna, Vincenza Conteduca, Emanuela Bianchi, Francesca Fabbri, Elisa Carretta, Dino Amadori, Giovanni Paganelli, Federica Matteucci

Preuzmi cijeli tekst Preuzmi cijeli tekst

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment od Michele Iuliani, Francesco Pantano, Consuelo Buttigliero, Marco Fioramonti, Valentina Bertaglia, Bruno Vincenzi, Alice Zoccoli, Giulia Ribelli, Marcello Tucci, Francesca Vignani, Alfredo Berruti, Giorgio V. Scagliotti, Giuseppe Tonini, Daniele Santini

Preuzmi cijeli tekst Preuzmi cijeli tekst

Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA... od Fred Saad, Neal D. Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul N. Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas A. Griffin, Peter De Porre, Anil Londhe, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan

Preuzmi cijeli tekst

Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer od Zhenfei Li, Andrew C. Bishop, Mohammad Alyamani, Jorge A. García, Robert Dreicer, Dustin R. Bunch, Jiayan Liu, Sunil Upadhyay, Richard J. Auchus, Nima Sharifi

Preuzmi cijeli tekst

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate‐resistant prostate cancer previously treated with do... od Michel D. Wissing, Jules L.L.M. Coenen, Pieter van den Berg, Hans M. Westgeest, Alfons J.M. van den Eertwegh, Inge M. van Oort, Monique M.E.M. Bos, Andries M. Bergman, Paul Hamberg, Albert J. ten Tije, Maartje Los, Martijn P. Lolkema, Ronald de Wit, Hans Gelderblom

Preuzmi cijeli tekst Preuzmi cijeli tekst

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer od Consuelo Buttigliero, Marcello Tucci, Valentina Bertaglia, Francesca Vignani, Paolo Bironzo, Massimo Di Maïo, Giorgio V. Scagliotti

Preuzmi cijeli tekst

Androgen pathway resistance in prostate cancer and therapeutic implications od Benjamin L. Maughan, Emmanuel S. Antonarakis

Preuzmi cijeli tekst

Targeting molecular resistance in castration-resistant prostate cancer od Thenappan Chandrasekar, Joy C. Yang, Allen C. Gao, Christopher P. Evans

Preuzmi cijeli tekst Preuzmi cijeli tekst

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer od Karim Fizazi, Laurence Albigès, Yohann Loriot, Christophe Massard

Preuzmi cijeli tekst Preuzmi cijeli tekst

Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer od Emmanuel S. Antonarakis, Andrew J. Armstrong

Preuzmi cijeli tekst

CYP17A1 inhibitors in castration-resistant prostate cancer od Lissette Gomez, Jason R. Kovac, Dolores J. Lamb

Preuzmi cijeli tekst

Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 od Natasha M. DeVore, Emily E. Scott

Preuzmi cijeli tekst

Abiraterone in the treatment of metastatic castration-resistant prostate cancer od Elahe A. Mostaghel

Preuzmi cijeli tekst Preuzmi cijeli tekst

CYP17 inhibitors for prostate cancer therapy od Tadas S. Vasaitis, Robert D. Bruno, Vincent C.O. Njar

Preuzmi cijeli tekst

Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo stud... od Jef Stappaerts, Sophie Geboers, Jan Snoeys, Joachim Brouwers, Jan Tack, Pieter Annaert, Patrick Augustijns

Preuzmi cijeli tekst

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison od Pui San Tan, Benjamin Haaland, Alberto J. Montero, Christos E. Kyriakopoulos, Gilberto Lopes

Preuzmi cijeli tekst Preuzmi cijeli tekst

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302) od Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul N. Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel, Joan Carles, Thomas W. Flaig, Eleni Efstathiou, Evan Y. Yu, Celestia S. Higano, Mary-Ellen Taplin, Thomas W. Griffin, Mary B. Todd, Margaret K. Yu, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan, Fred Saad

Preuzmi cijeli tekst

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy od Charles G. Drake, Padmanee Sharma, Winald R. Gerritsen

Preuzmi cijeli tekst

Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences od K-H Chang, Cesar E. Ercole, Nima Sharifi

Preuzmi cijeli tekst Preuzmi cijeli tekst

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer od Yasser Rehman, Yasser Rehman

Preuzmi cijeli tekst Preuzmi cijeli tekst